154 related articles for article (PubMed ID: 32880259)
1. HIV-1 diversity and the implementation of integrase strand-transfer inhibitors as part of combination antiretroviral therapy.
Mikasi SG; Ikomey GM; Obasa AE; Cloete R; Jacobs GB
S Afr Med J; 2020 Aug; 110(9):13071. PubMed ID: 32880259
[No Abstract] [Full Text] [Related]
2. The promise of paediatric dolutegravir.
Golin R; Samuel JM; Phelps BR; Persaud U; Malati CY; Siberry GK
J Int AIDS Soc; 2021 Jan; 24(1):e25660. PubMed ID: 33522081
[No Abstract] [Full Text] [Related]
3. Dosing of Dolutegravir in TB/HIV Coinfected Patients on Rifampicin: Twice Is (Always) Better Than Once.
Cattaneo D; Riva A; Columpsi P; Lapadula G; Filice C; Gervasoni C
J Acquir Immune Defic Syndr; 2020 Jul; 84(3):e17-e20. PubMed ID: 32205722
[No Abstract] [Full Text] [Related]
4. Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.
Viani RM; Ruel T; Alvero C; Fenton T; Acosta EP; Hazra R; Townley E; Palumbo P; Buchanan AM; Vavro C; Singh R; Graham B; Anthony P; George K; Wiznia A;
J Pediatric Infect Dis Soc; 2020 Apr; 9(2):159-165. PubMed ID: 30951600
[TBL] [Abstract][Full Text] [Related]
5. Multiple choices for HIV therapy with integrase strand transfer inhibitors.
Raffi F; Wainberg MA
Retrovirology; 2012 Dec; 9():110. PubMed ID: 23253887
[TBL] [Abstract][Full Text] [Related]
6. Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations.
Mikasi SG; Isaacs D; Chitongo R; Ikomey GM; Jacobs GB; Cloete R
BMC Infect Dis; 2021 Apr; 21(1):379. PubMed ID: 33892628
[TBL] [Abstract][Full Text] [Related]
7. Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa.
Salou M; Butel C; Comlan AS; Konou AA; Tegueni K; Ehlan A; Lack F; Dossim S; Ayouba A; Delaporte E; Dagnra AY; Peeters M
AIDS; 2020 Apr; 34(5):783-787. PubMed ID: 31895149
[TBL] [Abstract][Full Text] [Related]
8. Low-cost urine tenofovir assay to triage dolutegravir resistance testing.
Martinson T; Nwogu-Attah J; Spinelli M; Gandhi M
Lancet HIV; 2024 May; 11(5):e282-e283. PubMed ID: 38461845
[No Abstract] [Full Text] [Related]
9. Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients.
Nasreddine R; Florence E; Vandercam B; Moutschen M; Goffard JC; De Munter P; Delforge M; Marinus W; De Wit S;
AIDS; 2020 Jul; 34(8):1151-1159. PubMed ID: 32287063
[TBL] [Abstract][Full Text] [Related]
10. Effect of Dolutegravir and Sertraline on the Blood Brain Barrier (BBB).
Ma Q; Schifitto G; Venuto C; Ocque A; Dewhurst S; Morse GD; Aalinkeel R; Schwartz SA; Mahajan SD
J Neuroimmune Pharmacol; 2020 Mar; 15(1):7-9. PubMed ID: 31939069
[No Abstract] [Full Text] [Related]
11. Is resistance to dolutegravir possible when this drug is used in first-line therapy?
Mesplède T; Wainberg MA
Viruses; 2014 Aug; 6(9):3377-85. PubMed ID: 25166745
[TBL] [Abstract][Full Text] [Related]
12. Dolutegravir drug-resistance monitoring in Africa.
Kouamou V; Inzaule S; Manasa J
Lancet HIV; 2021 Nov; 8(11):e664-e666. PubMed ID: 34735801
[No Abstract] [Full Text] [Related]
13. Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir.
Fulcher JA; Du Y; Zhang TH; Sun R; Landovitz RJ
Clin Infect Dis; 2018 Aug; 67(5):791-794. PubMed ID: 29933437
[TBL] [Abstract][Full Text] [Related]
14. Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling.
Liu XI; Momper JD; Rakhmanina NY; Green DJ; Burckart GJ; Cressey TR; Mirochnick M; Best BM; van den Anker JN; Dallmann A
Clin Pharmacokinet; 2020 Nov; 59(11):1433-1450. PubMed ID: 32451908
[TBL] [Abstract][Full Text] [Related]
15. Two drugs regimens for HIV.
Waters L; Church H
Curr Opin Infect Dis; 2020 Feb; 33(1):28-33. PubMed ID: 31834030
[TBL] [Abstract][Full Text] [Related]
16. Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection.
Boffito M; Waters L; Cahn P; Paredes R; Koteff J; Van Wyk J; Vincent T; Demarest J; Adkison K; Quercia R
AIDS Res Hum Retroviruses; 2020 Jan; 36(1):13-18. PubMed ID: 31507204
[TBL] [Abstract][Full Text] [Related]
17. Comparison of an in-house 'home-brew' and commercial ViroSeq integrase genotyping assays on HIV-1 subtype C samples.
Seatla KK; Choga WT; Mogwele M; Diphoko T; Maruapula D; Mupfumi L; Musonda RM; Rowley CF; Avalos A; Kasvosve I; Moyo S; Gaseitsiwe S
PLoS One; 2019; 14(11):e0224292. PubMed ID: 31751353
[TBL] [Abstract][Full Text] [Related]
18. The impact of integrase inhibitor-based regimens on markers of inflammation among HIV naïve patients.
Quiros-Roldan E; Castelli F; Bonito A; Vezzoli M; Calza S; Biasiotto G; Zanella I;
Cytokine; 2020 Feb; 126():154884. PubMed ID: 31670006
[TBL] [Abstract][Full Text] [Related]
19. Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice.
Ciccullo A; Baldin G; Cossu MV; Passerini M; Borghetti A; Capetti A; Di Giambenedetto S
AIDS Res Hum Retroviruses; 2020 Jan; 36(1):4-5. PubMed ID: 31476877
[No Abstract] [Full Text] [Related]
20. Concerns and clarifications regarding the article 'Virological, weight, and drug resistance outcomes among patients initiating a dolutegravir-based first line ART regimen in Zimbabwe'.
Karabay O
AIDS; 2024 Jul; 38(8):1273. PubMed ID: 38814717
[No Abstract] [Full Text] [Related]
[Next] [New Search]
